Hepatocellular Carcinoma
1,842
291
388
577
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
169 trials with published results (9%)
Research Maturity
577 completed trials (31% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.7%
161 terminated out of 1842 trials
78.2%
-8.4% vs benchmark
11%
208 trials in Phase 3/4
29%
169 of 577 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 577 completed trials
Clinical Trials (1842)
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
TheraSphere With Durvalumab and Tremelimumab for HCC
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
LEOPARD Prospective Validation Cohort 1
LEOPARD Training and Validation Data Collection Study
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
IDOV-Immune for Advanced Solid Tumors
Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors